Oncology

Latest News

New OTC Colon Cancer Test Makes Screening More Accessible, Affordable
New OTC Colon Cancer Test Makes Screening More Accessible, Affordable

March 25th 2024

Jeffrey Reese, president at Reese Pharmaceutical, discusses what sets ColoTest apart from other at-home colorectal cancer screening tests.

Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer Gets Full FDA Approval
Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer Gets Full FDA Approval

March 22nd 2024

Blood-Based Test Demonstrates High Sensitivity for Colorectal Cancer
Blood-Based Test Demonstrates High Sensitivity for Colorectal Cancer

March 15th 2024

FDA Approves Lisocabtagene Maraleucel For Treatment of Relapsed or Refractory CLL, SLL
FDA Approves Lisocabtagene Maraleucel For Treatment of Relapsed or Refractory CLL, SLL

March 15th 2024

FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma
FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma

March 8th 2024

Latest CME Events & Activities

Risks and Liabilities in Pharmacy Practice

1.0 Credit / Law

View More

Optimizing the Use of Targeted Therapies for the Treatment of ROS1-Rearranged and KRAS-Mutant Non−Small Cell Lung Cancer

1.0 Credits / Oncology

View More

An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC

2 Credits / Oncology, Pulmonology/Respiratory

View More

Exploring the New Standard of Care for the Frontline Treatment of Non-Small Cell Lung Cancer: A Focus on Immunotherapy

1.5 Credits / Oncology, Pulmonology/Respiratory

View More

2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care

1.0 Credit / Oncology

View More

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

1.5 Credits / Hematology, Oncology

View More

Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL

2.0 Credits / Hematology, Oncology

View More

Precision Oncology in Practice: Transforming Non–Small Cell Lung Cancer Care Through Advanced Biomarker Testing

April 4, 2024 | 2:25 PM ET

View More

Navigating the Use of Bispecific Antibodies in Non-Hodgkin Lymphoma: Solutions to Enhance Community-Based Care

April 4, 2024 | 11:50 AM ET

View More

Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell Therapies and Bispecific Antibodies in Multiple Myeloma

April 4, 2024 | 11:00 AM ET

View More

Ensuring the Safe, Effective, and Equitable Care of Patients With Advanced Endometrial Cancer: Strategies for Oncology Pharmacists

April 4, 2024 | 1:35 PM ET

View More

COA Virtual Broadcasts

April 4-5, 2024

View More

Navigating Myelofibrosis: Tailored Treatments and Holistic Patient Support

April 5, 2024 | 11:00 AM ET

View More

Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia

1.5 Credits / Hematology, Oncology

View More

Evidence and Managed Care Considerations for the Use of Novel Immunotherapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1.5 Credits / Oncology

View More

Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes

1.5 Credits / Hematology, Oncology

View More

Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens

1.0 Credit / Hematology, Oncology

View More

Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role

1.0 Credit / Hematology, Oncology

View More

Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens

1.0 Credit / Hematology, Oncology

View More

Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care

1.0 Credit / Hematology, Oncology

View More

Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy

1.0 Credit / Hematology, Oncology

View More

Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives

1.0 Credit / Hematology, Oncology

View More

Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions

1.0 Credit / Oncology

View More

Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure

1.0 Credit / Oncology

View More

Optimizing Treatment of Early-Stage Breast Cancer and the Pharmacist’s Role in Managing Targeted Therapies

1.5 Credits / Oncology

View More

Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care

1.0 Credit / Oncology, Pulmonology/Respiratory

View More

Enhancing Care for Patients With Endometrial Cancer Through Pharmacist Interventions

1.0 Credit / Oncology, Women’s Health

View More

Clinical Updates and Strategies for Optimizing Use of Bispecific Antibodies in Hematologic Malignancies

1.0 Credit / Oncology

View More

Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure

1.0 Credit / Oncology

View More

More News

© 2024 MJH Life Sciences

All rights reserved.